(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering...
Stats | |
---|---|
今日成交量 | 2.19M |
平均成交量 | 2.29M |
市值 | 15.50M |
EPS | $0 ( 2024-04-01 ) |
下一个收益日期 | ( $-0.520 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0300 |
ATR14 | $0.00100 (0.53%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 1 903 680 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 235 320 | Stock Option |
2024-02-27 | Saenger Bradley | Buy | 282 000 | Stock Option |
INSIDER POWER |
---|
99.09 |
Last 97 transactions |
Buy: 77 144 979 | Sell: 389 187 |
音量 相关性
Tonix Pharmaceuticals 相关性 - 货币/商品
Tonix Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $7.77M |
毛利润: | $-1.26M (-16.27 %) |
EPS: | $-6.85 |
FY | 2023 |
营收: | $7.77M |
毛利润: | $-1.26M (-16.27 %) |
EPS: | $-6.85 |
FY | 2022 |
营收: | $0 |
毛利润: | $-112.09M (0.00 %) |
EPS: | $-20.11 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.976 |
Financial Reports:
No articles found.
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。